Tissue | Expression Dynamics | Abbreviation |
Cervix | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Cervix/ATR_pca_on_diff_genes.png) | CC: Cervix cancer |
HSIL_HPV: HPV-infected high-grade squamous intraepithelial lesions |
N_HPV: HPV-infected normal cervix |
Colorectum (GSE201348) | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Colorectum/Becker/ATR_pca_on_diff_genes.png) | FAP: Familial adenomatous polyposis |
CRC: Colorectal cancer |
Colorectum (HTA11) | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Colorectum/Chen/ATR_pca_on_diff_genes.png) | AD: Adenomas |
SER: Sessile serrated lesions |
MSI-H: Microsatellite-high colorectal cancer |
MSS: Microsatellite stable colorectal cancer |
Esophagus | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Esophagus/ATR_pca_on_diff_genes.png) | ESCC: Esophageal squamous cell carcinoma |
HGIN: High-grade intraepithelial neoplasias |
LGIN: Low-grade intraepithelial neoplasias |
Liver | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Liver/ATR_pca_on_diff_genes.png) | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
Lung | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Lung/ATR_pca_on_diff_genes.png) | AAH: Atypical adenomatous hyperplasia |
AIS: Adenocarcinoma in situ |
IAC: Invasive lung adenocarcinoma |
MIA: Minimally invasive adenocarcinoma |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:001657114 | Skin | cSCC | histone methylation | 52/4864 | 141/18723 | 2.74e-03 | 1.54e-02 | 52 |
GO:004508812 | Skin | cSCC | regulation of innate immune response | 75/4864 | 218/18723 | 3.40e-03 | 1.84e-02 | 75 |
GO:00711031 | Skin | cSCC | DNA conformation change | 96/4864 | 290/18723 | 3.87e-03 | 2.07e-02 | 96 |
GO:000979122 | Skin | cSCC | post-embryonic development | 32/4864 | 80/18723 | 4.18e-03 | 2.21e-02 | 32 |
GO:00085845 | Skin | cSCC | male gonad development | 51/4864 | 141/18723 | 4.70e-03 | 2.40e-02 | 51 |
GO:00465465 | Skin | cSCC | development of primary male sexual characteristics | 51/4864 | 142/18723 | 5.52e-03 | 2.73e-02 | 51 |
GO:004574011 | Skin | cSCC | positive regulation of DNA replication | 18/4864 | 40/18723 | 7.10e-03 | 3.40e-02 | 18 |
GO:2000232 | Skin | cSCC | regulation of rRNA processing | 9/4864 | 16/18723 | 9.73e-03 | 4.31e-02 | 9 |
GO:003106014 | Skin | cSCC | regulation of histone methylation | 27/4864 | 69/18723 | 1.13e-02 | 4.92e-02 | 27 |
GO:004217630 | Thyroid | HT | regulation of protein catabolic process | 70/1272 | 391/18723 | 5.96e-14 | 1.66e-11 | 70 |
GO:190336230 | Thyroid | HT | regulation of cellular protein catabolic process | 50/1272 | 255/18723 | 7.98e-12 | 1.48e-09 | 50 |
GO:000989528 | Thyroid | HT | negative regulation of catabolic process | 50/1272 | 320/18723 | 2.72e-08 | 2.02e-06 | 50 |
GO:003133029 | Thyroid | HT | negative regulation of cellular catabolic process | 42/1272 | 262/18723 | 1.70e-07 | 9.25e-06 | 42 |
GO:00321039 | Thyroid | HT | positive regulation of response to external stimulus | 55/1272 | 427/18723 | 3.50e-06 | 1.16e-04 | 55 |
GO:00313497 | Thyroid | HT | positive regulation of defense response | 40/1272 | 278/18723 | 5.40e-06 | 1.66e-04 | 40 |
GO:000150320 | Thyroid | HT | ossification | 51/1272 | 408/18723 | 1.81e-05 | 4.29e-04 | 51 |
GO:004217726 | Thyroid | HT | negative regulation of protein catabolic process | 22/1272 | 121/18723 | 1.97e-05 | 4.60e-04 | 22 |
GO:00022536 | Thyroid | HT | activation of immune response | 47/1272 | 375/18723 | 3.55e-05 | 7.40e-04 | 47 |
GO:000164920 | Thyroid | HT | osteoblast differentiation | 32/1272 | 229/18723 | 8.06e-05 | 1.40e-03 | 32 |
GO:190336326 | Thyroid | HT | negative regulation of cellular protein catabolic process | 15/1272 | 75/18723 | 1.33e-04 | 2.10e-03 | 15 |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
hsa0421810 | Cervix | CC | Cellular senescence | 49/1267 | 156/8465 | 1.30e-07 | 1.63e-06 | 9.61e-07 | 49 |
hsa0516620 | Cervix | CC | Human T-cell leukemia virus 1 infection | 61/1267 | 222/8465 | 8.13e-07 | 7.98e-06 | 4.72e-06 | 61 |
hsa0517016 | Cervix | CC | Human immunodeficiency virus 1 infection | 55/1267 | 212/8465 | 1.80e-05 | 1.42e-04 | 8.40e-05 | 55 |
hsa051657 | Cervix | CC | Human papillomavirus infection | 74/1267 | 331/8465 | 1.70e-04 | 1.02e-03 | 6.03e-04 | 74 |
hsa041106 | Cervix | CC | Cell cycle | 36/1267 | 157/8465 | 4.94e-03 | 1.67e-02 | 9.86e-03 | 36 |
hsa0421815 | Cervix | CC | Cellular senescence | 49/1267 | 156/8465 | 1.30e-07 | 1.63e-06 | 9.61e-07 | 49 |
hsa05166110 | Cervix | CC | Human T-cell leukemia virus 1 infection | 61/1267 | 222/8465 | 8.13e-07 | 7.98e-06 | 4.72e-06 | 61 |
hsa0517017 | Cervix | CC | Human immunodeficiency virus 1 infection | 55/1267 | 212/8465 | 1.80e-05 | 1.42e-04 | 8.40e-05 | 55 |
hsa0516512 | Cervix | CC | Human papillomavirus infection | 74/1267 | 331/8465 | 1.70e-04 | 1.02e-03 | 6.03e-04 | 74 |
hsa0411013 | Cervix | CC | Cell cycle | 36/1267 | 157/8465 | 4.94e-03 | 1.67e-02 | 9.86e-03 | 36 |
hsa05170 | Colorectum | AD | Human immunodeficiency virus 1 infection | 72/2092 | 212/8465 | 1.40e-03 | 8.46e-03 | 5.39e-03 | 72 |
hsa05166 | Colorectum | AD | Human T-cell leukemia virus 1 infection | 72/2092 | 222/8465 | 5.24e-03 | 2.44e-02 | 1.55e-02 | 72 |
hsa051701 | Colorectum | AD | Human immunodeficiency virus 1 infection | 72/2092 | 212/8465 | 1.40e-03 | 8.46e-03 | 5.39e-03 | 72 |
hsa051661 | Colorectum | AD | Human T-cell leukemia virus 1 infection | 72/2092 | 222/8465 | 5.24e-03 | 2.44e-02 | 1.55e-02 | 72 |
hsa051702 | Colorectum | SER | Human immunodeficiency virus 1 infection | 58/1580 | 212/8465 | 1.08e-03 | 8.56e-03 | 6.21e-03 | 58 |
hsa051703 | Colorectum | SER | Human immunodeficiency virus 1 infection | 58/1580 | 212/8465 | 1.08e-03 | 8.56e-03 | 6.21e-03 | 58 |
hsa051704 | Colorectum | MSS | Human immunodeficiency virus 1 infection | 69/1875 | 212/8465 | 2.66e-04 | 1.98e-03 | 1.21e-03 | 69 |
hsa042182 | Colorectum | MSS | Cellular senescence | 52/1875 | 156/8465 | 7.87e-04 | 5.07e-03 | 3.11e-03 | 52 |
hsa051662 | Colorectum | MSS | Human T-cell leukemia virus 1 infection | 68/1875 | 222/8465 | 1.84e-03 | 9.61e-03 | 5.89e-03 | 68 |
hsa051705 | Colorectum | MSS | Human immunodeficiency virus 1 infection | 69/1875 | 212/8465 | 2.66e-04 | 1.98e-03 | 1.21e-03 | 69 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
ATR | SNV | Missense_Mutation | novel | c.6307G>A | p.Glu2103Lys | p.E2103K | Q13535 | protein_coding | deleterious(0.01) | benign(0.075) | TCGA-5L-AAT0-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | tamoxiphen | SD |
ATR | SNV | Missense_Mutation | novel | c.5518G>C | p.Glu1840Gln | p.E1840Q | Q13535 | protein_coding | deleterious(0) | probably_damaging(0.993) | TCGA-5L-AAT0-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | tamoxiphen | SD |
ATR | SNV | Missense_Mutation | rs762196224 | c.7724N>T | p.Ala2575Val | p.A2575V | Q13535 | protein_coding | tolerated(0.07) | benign(0.304) | TCGA-A2-A04W-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cytoxan | SD |
ATR | SNV | Missense_Mutation | | c.6400G>T | p.Ala2134Ser | p.A2134S | Q13535 | protein_coding | tolerated(0.12) | benign(0.021) | TCGA-A8-A09Z-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
ATR | SNV | Missense_Mutation | | c.2246N>G | p.Ser749Cys | p.S749C | Q13535 | protein_coding | tolerated(0.11) | benign(0.001) | TCGA-AC-A23H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD |
ATR | SNV | Missense_Mutation | rs746049210 | c.7219N>T | p.Arg2407Cys | p.R2407C | Q13535 | protein_coding | deleterious(0) | probably_damaging(0.943) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
ATR | SNV | Missense_Mutation | rs780802796 | c.3548N>A | p.Arg1183Gln | p.R1183Q | Q13535 | protein_coding | tolerated(0.11) | possibly_damaging(0.688) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
ATR | SNV | Missense_Mutation | rs369309229 | c.6196N>T | p.Arg2066Trp | p.R2066W | Q13535 | protein_coding | tolerated(0.08) | probably_damaging(0.939) | TCGA-AO-A128-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | SD |
ATR | SNV | Missense_Mutation | | c.226N>C | p.Met76Leu | p.M76L | Q13535 | protein_coding | tolerated_low_confidence(0.05) | benign(0.01) | TCGA-C8-A1HJ-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
ATR | SNV | Missense_Mutation | novel | c.4627N>C | p.Glu1543Gln | p.E1543Q | Q13535 | protein_coding | tolerated(0.11) | possibly_damaging(0.743) | TCGA-C8-A8HP-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | 5-fluorouracil | CR |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
545 | ATR | SERINE THREONINE KINASE, DNA REPAIR, CLINICALLY ACTIONABLE, ENZYME, KINASE, DRUGGABLE GENOME, PHOSPHATIDYLINOSITOL 3 KINASE | | M4344 | | |
545 | ATR | SERINE THREONINE KINASE, DNA REPAIR, CLINICALLY ACTIONABLE, ENZYME, KINASE, DRUGGABLE GENOME, PHOSPHATIDYLINOSITOL 3 KINASE | | E7449 | 2X-121 | |
545 | ATR | SERINE THREONINE KINASE, DNA REPAIR, CLINICALLY ACTIONABLE, ENZYME, KINASE, DRUGGABLE GENOME, PHOSPHATIDYLINOSITOL 3 KINASE | inhibitor | 384403635 | | |
545 | ATR | SERINE THREONINE KINASE, DNA REPAIR, CLINICALLY ACTIONABLE, ENZYME, KINASE, DRUGGABLE GENOME, PHOSPHATIDYLINOSITOL 3 KINASE | inhibitor | CHEMBL3545178 | CERALASERTIB | |
545 | ATR | SERINE THREONINE KINASE, DNA REPAIR, CLINICALLY ACTIONABLE, ENZYME, KINASE, DRUGGABLE GENOME, PHOSPHATIDYLINOSITOL 3 KINASE | inhibitor | 328083492 | CERALASERTIB | |
545 | ATR | SERINE THREONINE KINASE, DNA REPAIR, CLINICALLY ACTIONABLE, ENZYME, KINASE, DRUGGABLE GENOME, PHOSPHATIDYLINOSITOL 3 KINASE | inhibitor | 249565722 | | |
545 | ATR | SERINE THREONINE KINASE, DNA REPAIR, CLINICALLY ACTIONABLE, ENZYME, KINASE, DRUGGABLE GENOME, PHOSPHATIDYLINOSITOL 3 KINASE | | CISPLATIN | CISPLATIN | 12894503 |
545 | ATR | SERINE THREONINE KINASE, DNA REPAIR, CLINICALLY ACTIONABLE, ENZYME, KINASE, DRUGGABLE GENOME, PHOSPHATIDYLINOSITOL 3 KINASE | inhibitor | 249565633 | DACTOLISIB | |
545 | ATR | SERINE THREONINE KINASE, DNA REPAIR, CLINICALLY ACTIONABLE, ENZYME, KINASE, DRUGGABLE GENOME, PHOSPHATIDYLINOSITOL 3 KINASE | | BMN673 | | |
545 | ATR | SERINE THREONINE KINASE, DNA REPAIR, CLINICALLY ACTIONABLE, ENZYME, KINASE, DRUGGABLE GENOME, PHOSPHATIDYLINOSITOL 3 KINASE | inhibitor | 252166686 | | |